ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy

Liu, Diankun; Zhou, Qiang; Wang, Di; Qu, Yuan; Guo, Qihong; Wen, Jing; Yu, Qinghong*; Ai, Jun*南方医科大学; 1
Lupus2022-10DOI: 10.1177/09612033221119123
1被引11阅读
引用收藏
分享

摘要

Background Systemic lupus erythematosus is a chronic inflammatory autoimmune disease that has various manifestations. Lupus nephritis is a common and severe presentation, which results in increased morbidity and mortality. Belimumab added on standard therapy has been proved to induce disease remission and improve renal parameters. However, the use of belimumab has not been explored in patients requiring dialysis treatment. Methods Seven patients diagnosed as SLE with renal involvement requiring dialysis, who received belimumab in addition to steroids or immunosuppressants were identified. Clinical and biological data were extracted from medical records and laboratory databases. Ten mg/kg belimumab was applied on day 1, 15, 29, and every 28 days thereafter for a total of 8 dose. Renal parameters including urine output and serum creatinine level, immunologic index including anti-ds-DNA antibody titer and complement level, and disease activity were documented to reveal the response to belimumab. Results After belimumab therapy, all the 7 patients receiving dialysis therapy showed immunologic improvement. Disease activity significantly declined from 16.5 to 5.33 using SLEDAI-2K score. Apart from patient 7 on maintenance dialysis, 5 of 6 patients had increased urine output and were out of dialysis treatment. Patient 5 and 6 showed significant decrease in serum creatinine level. Only one pulmonary infection was documented. Conclusions Belimumab added to steroids or immunosuppressive agents was able to improve renal and immunologic parameters and decrease disease activity of SLE patients receiving dialysis treatment. The safety issue is promising with no severe adverse effect recorded. Further large, controlled, randomized clinical trials are required to confirm the results.

学科与关键词

关键词
belimumabsystemic lupus erythematosuslupus nephritisrenal replacement therapy
相关
加载中…
  • Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study
    Zhang, Shuoyang; Qiu, Qian; Zeng, Shan; Li, Hao; Xu, Liujing; Jie, Ligang; Hu, Xuejun; Xiao, Youjun; Chen, Dongying; Zhan, Zhongping; Liang, Liuqin*; Yu, Qinghong*; Xu, Hanshi*CLINICAL RHEUMATOLOGY, 2023.
  • Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
    Zhang, Fengchun; Zheng, Jie; Li, Yang; Wang, Guochun; Wang, Mingjun; Su, Yin; Gu, Jieruo; Li, Xingfu; Bass, Damon; Chu, Myron; Curtis, Paula; DeRose, Kathleen*; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A.RMD Open, 2022, 8(1): e001669.被引 4
  • Belimumab in childhood systemic lupus erythematosus: A review of available data
    Chen, Feng; Zheng, Ying; Chen, Xinying; Wen, Zhanfa; Xu, Youjia*; Yang, Jinghua*; Xu, Kaisi*Frontiers in Immunology, 2022, 13: 940416.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Lupus
发表日期
2022-10
卷期
第 31 卷, 第 12 期
页码
1456-1467
DOI
10.1177/09612033221119123
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Guangdong Provincial Clinical Research Center for Kidney Disease [2020B1111170013]; National Nature Science Foundation of China [81770765]

作者

  • L

    Liu, Diankun (第一作者)

    southern med univ

  • Z

    Zhou, Qiang

    peoples hosp guizhou prov

查看全部 8 位作者收起作者
  • W

    Wang, Di

    southern med univ

  • Q

    Qu, Yuan

    southern med univ

  • G

    Guo, Qihong

    foshan hosp tradit chinese med

  • W

    Wen, Jing

    1 · guangxi med univ

  • Y

    Yu, Qinghong (通讯)

    southern med univ

  • A

    Ai, Jun (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417